← Back to Search
A Novel Inhibitor Of Gyrase B Is A Potent Drug Candidate For Treatment Of Tuberculosis And Nontuberculosis Mycobacterial Infections
Christopher P Locher, S. Jones, Brian L Hanzelka, E. Perola, C. Shoen, M. Cynamon, A. Ngwane, I. Wiid, P. V. van Helden, Fabrice Betoudji, E. Nuermberger, J. A. Thomson
Published 2014 · Biology, Medicine
Save to my Library
Download PDFAnalyze on Scholarcy
ABSTRACT New drugs to treat drug-resistant tuberculosis are urgently needed. Extensively drug-resistant and probably the totally drug-resistant tuberculosis strains are resistant to fluoroquinolones like moxifloxacin, which target gyrase A, and most people infected with these strains die within a year. In this study, we found that a novel aminobenzimidazole, VXc-486, which targets gyrase B, potently inhibits multiple drug-sensitive isolates and drug-resistant isolates of Mycobacterium tuberculosis in vitro (MICs of 0.03 to 0.30 μg/ml and 0.08 to 5.48 μg/ml, respectively) and reduces mycobacterial burdens in lungs of infected mice in vivo. VXc-486 is active against drug-resistant isolates, has bactericidal activity, and kills intracellular and dormant M. tuberculosis bacteria in a low-oxygen environment. Furthermore, we found that VXc-486 inhibits the growth of multiple strains of Mycobacterium abscessus, Mycobacterium avium complex, and Mycobacterium kansasii (MICs of 0.1 to 2.0 μg/ml), as well as that of several strains of Nocardia spp. (MICs of 0.1 to 1.0 μg/ml). We made a direct comparison of the parent compound VXc-486 and a phosphate prodrug of VXc-486 and showed that the prodrug of VXc-486 had more potent killing of M. tuberculosis than did VXc-486 in vivo. In combination with other antimycobacterial drugs, the prodrug of VXc-486 sterilized M. tuberculosis infection when combined with rifapentine-pyrazinamide and bedaquiline-pyrazinamide in a relapse infection study in mice. Furthermore, the prodrug of VXc-486 appeared to perform at least as well as the gyrase A inhibitor moxifloxacin. These findings warrant further development of the prodrug of VXc-486 for the treatment of tuberculosis and nontuberculosis mycobacterial infections.
This paper references
Paradoxical Effect of Isoniazid on the Activity of Rifampin-Pyrazinamide Combination in a Mouse Model of Tuberculosis
Deepak V. Almeida (2009)
Novel dual-targeting benzimidazole urea inhibitors of DNA gyrase and topoisomerase IV possessing potent antibacterial activity: intelligent design and evolution through the judicious use of structure-guided design and structure-activity relationships.
P. Charifson (2008)
Optimization of Pyrrolamides as Mycobacterial GyrB ATPase Inhibitors: Structure-Activity Relationship and In Vivo Efficacy in a Mouse Model of Tuberculosis
Shahul Hameed P (2013)
Bactec MGIT 960 system user’s manual, catalog number 445876
Becton Dickinson (1999)
Second-generation antibacterial benzimidazole ureas: discovery of a preclinical candidate with reduced metabolic liability.
A. Grillot (2014)
Bactericidal Activity and Mechanism of Action of AZD5847, a Novel Oxazolidinone for Treatment of Tuberculosis
V. Balasubramanian (2013)
Fragment-to-hit-to-lead discovery of a novel pyridylurea scaffold of ATP competitive dual targeting type II topoisomerase inhibiting antibacterial agents.
G. Basarab (2013)
aac.asm.org March 2015 Volume 59 Number 3 Antimicrobial Agents and Chemotherapy on Jauary 8, 2018 by gest httpaac.asm .rg/ D ow nladed fom
S Hameed (2014)
Short-course treatment regimen to identify potential antituberculous agents in a murine model of tuberculosis.
C. Shoen (2004)
aac.asm.org March 2015 Volume 59 Number 3 Antimicrobial Agents and Chemotherapy
S Hameed (2014)
Fast Standardized Therapeutic-Efficacy Assay for Drug Discovery against Tuberculosis
J. Rullás (2010)
Low-Oxygen-Recovery Assay for High-Throughput Screening of Compounds against Nonreplicating Mycobacterium tuberculosis
Sang Hyun Cho (2007)
Mycobacterium tuberculosis DNA gyrase as a target for drug discovery.
Khisimuzi E Mdluli (2007)
Evaluation of gyrase B as a drug target in Mycobacterium tuberculosis.
S. Chopra (2012)
Thiazolopyridine ureas as novel antitubercular agents acting through inhibition of DNA Gyrase B.
M. Kale (2013)
In Vitro Characterization of the Antibacterial Spectrum of Novel Bacterial Type II Topoisomerase Inhibitors of the Aminobenzimidazole Class
N. Mani (2006)
Drug Susceptibility Testing
L. Heifets (1996)
Rapid, Low-Technology MIC Determination with Clinical Mycobacterium tuberculosis Isolates by Using the Microplate Alamar Blue Assay
S. Franzblau (1998)
Aminopyrazinamides: novel and specific GyrB inhibitors that kill replicating and nonreplicating Mycobacterium tuberculosis.
Pravin S. Shirude (2013)
Short-course chemotherapy with TMC207 and rifapentine in a murine model of latent tuberculosis infection.
Tianyu Zhang (2011)
Multicenter Laboratory Validation of the BACTEC MGIT 960 Technique for Testing Susceptibilities of Mycobacterium tuberculosis to Classical Second-Line Drugs and Newer Antimicrobials
S. Rüsch-Gerdes (2006)
Emergence and spread of extensively and totally drug-resistant tuberculosis, South Africa.
M. Klopper (2013)
Emergence and Spread of Extensively and Totally Drug-Resistant Tuberculosis, South Africa
M. Klopper (2013)
aac.asm.org March 2015 Volume 59 Number 3 Antimicrobial Agents and Chemotherapy on July 31, 2017 by gest httpaac.asm .rg/ D ow nladed fom
S Hameed (2014)
Thiazolopyridone ureas as DNA gyrase B inhibitors: optimization of antitubercular activity and efficacy.
Ramesh R. Kale (2014)
Tricyclic GyrB/ParE (TriBE) Inhibitors: A New Class of Broad-Spectrum Dual-Targeting Antibacterial Agents
L. W. Tari (2013)
Gyrase ATPase Domain as an Antitubercular Drug Discovery Platform: Structure‐Based Design and Lead Optimization of Nitrothiazolyl Carboxamide Analogues
V. U. Jeankumar (2014)
Paucibacillary Tuberculosis in Mice after Prior Aerosol Immunization with Mycobacterium bovis BCG
E. Nuermberger (2004)
The oxazolidinones: past, present, and future
K. Shaw (2011)
Pyrrolopyrimidine inhibitors of DNA gyrase B (GyrB) and topoisomerase IV (ParE), Part II: development of inhibitors with broad spectrum, Gram-negative antibacterial activity.
Micheal Trzoss (2013)
Global tuberculosis report (2014)
L. A. Gabbasova (2014)
Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination Studies
T. Chou (2006)
Dual Targeting of GyrB and ParE by a Novel Aminobenzimidazole Class of Antibacterial Compounds
T. Grossman (2006)
In vitro activity of BAY 12-8039, a new fluoroquinolone.
J. Woodcock (1997)
Clinical mycobacteriology. Drug susceptibility testing.
L. Heifets (1996)
In Vitro Activity of AZD5847 against Geographically Diverse Clinical Isolates of Mycobacterium tuberculosis
J. Werngren (2014)
Short-course therapy with daily rifapentine in a murine model of latent tuberculosis infection.
Tianyu Zhang (2009)
Mycobactericidal Activity of Sutezolid (PNU-100480) in Sputum (EBA) and Blood (WBA) of Patients with Pulmonary Tuberculosis
R. Wallis (2014)
This paper is referenced by
Structure-Based Drug Design for Tuberculosis: Challenges Still Ahead
E. Bruch (2020)
New prodrugs against tuberculosis.
G. Mori (2017)
Identification and optimization of a new series of anti-tubercular quinazolinones.
C. Couturier (2016)
2-N-Arylthiazole inhibitors of Mycobacterium tuberculosis.
M. P. Clark (2017)
In Vitro Susceptibility Testing of a Novel Benzimidazole, SPR719, against Nontuberculous Mycobacteria
B. Brown-Elliott (2018)
Targeting bacterial topoisomerases: how to counter mechanisms of resistance.
Yuk-Ching Tse-Dinh (2016)
Antibiotics in the clinical pipeline in October 2019
M. Butler (2020)
Targeting DNA Replication and Repair for the Development of Novel Therapeutics against Tuberculosis
M. Reiche (2017)
Targeting DNA Gyrase to Combat Mycobacterium tuberculosis: An Update.
Swetarka Das (2019)
Handling the Hurdles on the Way to Anti-tuberculosis Drug Development
P. F. Dalberto (2020)
News on therapeutic management of MDR-tuberculosis: a literature review
L. Barthod (2018)
The evaluation of the anti‐cancer drug elesclomol that forms a redox‐active copper chelate as a potential anti‐tubercular drug
A. Ngwane (2019)
New tuberculosis drug targets, their inhibitors and potential therapeutic impact.
Gauri S Shetye (2020)
Opportunities for Overcoming Mycobacterium tuberculosis Drug Resistance: Emerging Mycobacterial Targets and Host-Directed Therapy
Eveline Torfs (2019)
Strategies to improve treatment of nontuberculous mycobacterial disease
Belén Ramos (2017)
Pharmacotherapeutic management of bronchial infections in adults: non-cystic fibrosis bronchiectasis and chronic obstructive pulmonary disease
M. D. Di Pasquale (2020)
Alternative and Experimental Therapies of Mycobacterium abscessus Infections
Michal Meir (2020)
Moxifloxacin's Limited Efficacy in the Hollow-Fiber Model of Mycobacterium abscessus Disease
Beatriz E. Ferro (2016)
Screening of TB Actives for Activity against Nontuberculous Mycobacteria Delivers High Hit Rates
Jian Liang Low (2017)
Perspectives on antibiotic treatment of NTM pulmonary disease
Nicolas Schönfeld (2017)
Susceptibility of Mycobacterium abscessus to Antimycobacterial Drugs in Preclinical Models
A. Obregón-Henao (2015)
Médicaments et molécules innovantes en développement pour la prise en charge de la tuberculose
Léo Faïon (2019)
Looking beyond Typical Treatments for Atypical Mycobacteria
Clara M Bento (2020)
Dynamics of fluoroquinolones induced resistance in DNA gyrase of Mycobacterium tuberculosis
B. Pandey (2018)
ATP-competitive DNA gyrase and topoisomerase IV inhibitors as antibacterial agents
Martina Durcik (2019)
Infections caused by Mycobacterium abscessus: epidemiology, diagnostic tools and treatment
F. Mougari (2016)
Recent progress in the discovery and development of DNA gyrase B inhibitors.
M. Barančoková (2018)
Non-tuberculous mycobacteria and the rise of Mycobacterium abscessus
Matt D. Johansen (2020)